EU regulator conditionally approves bluebird bio\'s Zynteglo as first gene therapy for transfusiondependent betathalassaemia httpswww.firstwordpharma.comnode1644799Â $BLUE
EU regulator conditionally approves bluebird bio's Zynteglo as first gene therapy for transfusion-dependent beta-thalassaemia https://www.firstwordpharma.com/node/1644799 $BLUE
More From BioPortfolio on "EU regulator conditionally approves bluebird bio's Zynteglo as first gene therapy for transfusion-dependent beta-thalassaemia https://www.firstwordpharma.com/node/1644799 $BLUE"